Novel pharmacological approaches in abdominal aortic aneurysm

Area of Science:

• Vascular Biology and Medicine
• Cardiovascular Research
• Medical Therapeutics

Background:

• Abdominal aortic aneurysm (AAA) is a progressive dilation of the aorta, a significant public health concern with high mortality due to rupture.
• Major risk factors include atherosclerosis, aging, and smoking, yet effective pharmacological treatments are still lacking.
• Current management relies on surveillance for small aneurysms and surgical repair for high-risk patients.

Approach:

• This review synthesizes recent clinical and preclinical studies investigating novel therapeutic targets and pharmacological strategies for AAA.
• It examines the outcomes of past clinical trials using agents like antihypertensives, statins, doxycycline, and anti-platelet drugs.
• Ongoing trials, including those for metformin, and emerging preclinical findings are highlighted.

Key Points:

• No current pharmacological treatment effectively limits the growth of abdominal aortic aneurysms.
• Previous clinical trials with various drug classes have not demonstrated clear benefits in limiting AAA progression.
• Metformin's potential efficacy is under investigation, with results from ongoing trials eagerly awaited.
• Preclinical research is identifying new therapeutic targets and strategies for future clinical exploration.

Conclusions:

• There is an urgent unmet medical need for effective pharmacological therapies for abdominal aortic aneurysm (AAA).
• Despite extensive research, current medical interventions have failed to halt AAA growth, necessitating continued exploration of novel strategies.
• Future research focusing on new therapeutic targets identified in preclinical studies holds promise for developing effective AAA treatments.